[Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI rd 23 October 15, 2013 Division of Corporate Finance 100 F. Street, N.E. Attn: Jim B. Rosenberg Re: Tianyin Pharmaceutical Co, Inc. Item 4.01 Form 8-K Filed October 8, 2013 File No. 001-34189 Dear Mr. Rosenberg: This letter is provided in response to your letter dated October 9, 2013 regarding the above-referenced Form]
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 30, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 30, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[TPI Announces Fiscal Year 2013 Financial Results September 27, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2013. Fiscal Year 2013 Ended June 30, 2013 Financial Highlights: · Revenue was $67.5 million compared] [Tianyin Pharmaceutical Inc. Fiscal Year 2013 Annual Financial Results Conference Call September 27, 2013 Operator James Tong - Chief Financial Officer. Financial highlights of Fiscal year 2013 ended June 30, 2013: Revenue totaled $67.5 million compared with $69.6 million in fiscal year 2012, a decrease of 3% year-over-year. Operating income was $9.3 million, compared with $8.5 million in fiscal year] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 27, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[TPI Announces Fiscal Year 2013 Financial Results September 27, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2013. Fiscal Year 2013 Ended June 30, 2013 Financial Highlights: · Revenue was $67.5 million compared] [Tianyin Pharmaceutical Inc. Fiscal Year 2013 Annual Financial Results Conference Call September 27, 2013 Operator James Tong - Chief Financial Officer. Financial highlights of Fiscal year 2013 ended June 30, 2013: Revenue totaled $67.5 million compared with $69.6 million in fiscal year 2012, a decrease of 3% year-over-year. Operating income was $9.3 million, compared with $8.5 million in fiscal year] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 27, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
[Skystar Bio-Pharmaceuticalmpany Notice of Annual Meeting and Proxy Statement Annual Meeting to be held on October 25, 2013, at 4/F Building B Chuangye Square, No. 48 Keji Road, Gaoxin District, Xian, Shaanxi Province, P.R. China, at 7:45 pm, local timeYSTAR BIO-PHARMACEUTICALMPANY 4/F Building B Chuangye Square, No. 48 Keji Road,Gaoxin District, Xian, Shaanxi Province, P.R.]
